The ROE as of November 2024 (TTM) for Janux Therapeutics, Inc. (JANX) is -10.46%

According to Janux Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -10.46%. This represents a change of 285.87% compared to the average of -2.71% of the last 4 quarters.

Janux Therapeutics, Inc. (JANX) Historical ROE (quarterly & annually)

How has JANX ROE performed in the past?

The mean historical ROE of Janux Therapeutics, Inc. over the last ten years is 9.31%. The current -10.46% ROE has changed -212.44% with respect to the historical average. Over the past ten years (40 quarters), JANX's ROE was at its highest in in the March 2020 quarter at 35.79%. The ROE was at its lowest in in the June 2023 quarter at -5.85%.

Janux Therapeutics, Inc. (JANX) ROE by Quarter and Year

Discovering the peaks and valleys of Janux Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Janux Therapeutics, Inc. (JANX) Average ROE

How has JANX ROE performed in the past?

The current ROE of Janux Therapeutics, Inc. (JANX) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Janux Therapeutics, Inc. (JANX) ROE vs. Peers

How is JANX’s ROE compared to its peers?

Janux Therapeutics, Inc.’s ROE is greater than Mineralys Therapeutics, Inc. (-55.92%), greater than Eliem Therapeutics, Inc. (-47.03%), greater than Anebulo Pharmaceuticals, Inc. (-184.40%), greater than Rezolute, Inc. (-69.83%), greater than Keros Therapeutics, Inc. (-41.74%), less than Fennec Pharmaceuticals Inc. (31.99%), greater than Edgewise Therapeutics, Inc. (-26.83%), less than Harmony Biosciences Holdings, Inc. (23.16%), greater than Molecular Partners AG (-39.16%), greater than MediciNova, Inc. (-20.70%), less than Champions Oncology, Inc. (323.52%), greater than Cyteir Therapeutics, Inc. (-9.44%), greater than Aerovate Therapeutics, Inc. (-90.19%), greater than Adagene Inc. (-50.10%), greater than Acrivon Therapeutics, Inc. Common Stock (-47.95%), greater than AN2 Therapeutics, Inc. (-57.63%),

Build a custom stock screener for Janux Therapeutics, Inc. (JANX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Janux Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Janux Therapeutics, Inc. (JANX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Janux Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.